Xanodyne Pharmaceuticals, Inc.
http://www.xanodyne.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xanodyne Pharmaceuticals, Inc.
Stock Watch: J.P. Morgan Conference, Big Splash News And Stock Prices
Timing big M&A transactions to coincide with the biggest investor conference of the year is difficult. But getting it right can boost stocks across the sector.
Olema Flies Flag For SERDs, Planning Phase III Trials As Rivals Stumble
Several factors differentiate Olema Oncology’s lead drug candidate from the SERD herd, says its CEO Sean Bohen, as the firm looks to partner the ‘ready-for-Phase III multibillion-dollar asset.’
FDA’s Robyn Bent On The Evolution of Patient-Focused Drug Development
The director of the agency’s patient-focused drug development program talks about how the program has improved the development and evaluation of new drugs, initiatives underway, and plans to standardize and harmonize the process.
FDA’s Robyn Bent On The Evolution of Patient-Focused Drug Development
The director of the agency’s patient-focused drug development program talks to the Pink Sheet about how the program has improved the development and evaluation of new drugs, initiatives underway, and plans to standardize and harmonize the process.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice